Hanmi Pharm

Beta

KRX Filings & Disclosures 2026

Risk Factors

• • KRW 15B pre-tax impact from 10% KRW appreciation/depreciation on foreign currency exposure, up from KRW 12.2B prior year
• • KRW 1.17B earnings decrease from 1% interest rate increase on financial assets/liabilities, down from KRW 2.08B prior year

Management Discussion & Analysis

• • Total consolidated revenue KRW 1.5475T (+3.5% YoY), operating profit KRW 258B (+19.2%), net income KRW 187.1B (+33.3%)
• • Pharmaceutical segment revenue KRW 1.1466T (+2.9%) driven by Rosuzet’s 8.4% growth to KRW 227.9B in prescription sales and increased clinical supply and royalties

Business Overview

• • Pharmaceutical segment revenue KRW 1.15T led by Rosuzet and Amozaltan; exports from Hanmi Precision Chemistry to 40+ countries
• • New product launch: Mayaping (Amozaltan) in Beijing Hanmi China in 2022 fueling overseas growth

What are the latest Hanmi Pharm DART filings in 2026?

Hanmi Pharm (KRX code 128940) has filed an annual report on March 20, 2026 with DART. SignalX tracks every new DART disclosure with AI-powered English summaries of business overview, risk factors, and management discussion.

When did Hanmi Pharm file its most recent annual report?

Hanmi Pharm filed its most recent annual report on March 20, 2026. The annual report includes audited financial statements, business overview, risk factors, and management discussion (MD&A), all available on SignalX with AI-generated English summaries and KIFRS financial data.

What is Hanmi Pharm's KRX stock code?

Hanmi Pharm's KRX stock code is 128940. The 6-digit stock code is the KRX standard identifier for every listed security. You can use stock code 128940 to look up all Hanmi Pharm disclosures on DART, or browse them here on SignalX with AI-powered English analysis.

How often does Hanmi Pharm file with DART?

Korean listed companies file an annual report once per year (typically within 90 days of fiscal year-end), a half-year report once mid-year, and quarterly reports for Q1 and Q3 — three regular periodic disclosures plus the annual. Material event reports are filed as needed when corporate events occur. SignalX monitors DART daily.

What is the difference between annual, half-year, and quarterly reports in Korea?

An annual report is a comprehensive filing with audited financials, business overview, and risk factors — analogous to the US 10-K. A half-year (interim) report covers H1 results. Quarterly reports cover Q1 or Q3 — analogous to the US 10-Q but Korea publishes only two quarterly reports per year (with the half-year report covering Q2). SignalX provides AI-generated English summaries for all three filing types for Hanmi Pharm.

Where can I find Hanmi Pharm financial data and KIFRS metrics?

SignalX extracts KIFRS consolidated financial data from Hanmi Pharm annual reports, including revenue, gross profit, operating income, net income, total assets, stockholders' equity, EPS (basic/diluted), operating cash flow, and capital expenditure — all in KRW. Multi-year financial trends are displayed in the Financial Summary table above.